ClinicalTrials.gg
CompletedNCT06024239MADUpdated Mar 17, 2025

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

A Phase 1 interventional study of ABBV-932 and Placebo for ABBV-932 in Healthy Volunteers, Generalized Anxiety Disorder (GAD) and Bipolar Disorder (BPD), sponsored by AbbVie. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
133rd of 234
72 · median 90
Started
2023
with 9 others
Phase 1
10 of 265
2 open now
Registered
219th of 265
by date
Lead sponsor
5 of 265
AbbVie

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 133rd largest by enrollment of the 234 interventional ones that give a count, is one of 10 that started in 2023, is one of 10 in phase 1, and was the 219th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).

03

Conditions studied

  • Healthy Volunteers
  • Generalized Anxiety Disorder (GAD)
  • Bipolar Disorder (BPD)

Keywords

  • ABBV-932
  • Generalized Anxiety Disorder (GAD)
  • Bipolar Disorder (BPD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For healthy volunteer cohort:

    -- (BMI) is >= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal.

  • For participants with generalized anxiety disorder (GAD) or bipolar disorder (BPD)

    • Participants with GAD or BPD (as confirmed by MINI) meet participant psychiatric history criteria described in the protocol.

Exclusion criteria

Exclusion Criteria:

  • History of any illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Part A, ABBV-932

    Participants will receive ABBV-932 once daily (QD) for 14 days.

    Drug: ABBV-932

  • Experimental
    Part A, Placebo for ABBV-932

    Participants will receive placebo for ABBV-932 QD for 14 days.

    Drug: Placebo for ABBV-932

  • Experimental
    Part B, ABBV-932

    Participants will receive ABBV-932 QD for 28 days.

    Drug: ABBV-932

  • Experimental
    Part B, Placebo for ABBV-932

    Participants will receive placebo for ABBV-932 QD for 28 days.

    Drug: Placebo for ABBV-932

  • Experimental
    Part C, ABBV-932

    Participants will receive ABBV-932 QD for 28 days.

    Drug: ABBV-932

  • Experimental
    Part C, Placebo for ABBV-932

    Participants will receive placebo for ABBV-932 QD for 28 days.

    Drug: Placebo for ABBV-932

  • Experimental
    Part D, ABBV-932

    Participants will receive ABBV-932 QD for 42 days.

    Drug: ABBV-932

  • Experimental
    Part D, Placebo for ABBV-932

    Participants will receive placebo for ABBV-932 QD for 42 days.

    Drug: Placebo for ABBV-932

Interventions

  • Capsule; oral

  • DrugPlacebo for ABBV-932

    Capsule; oral

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Cmax will be assessed.

    Time frame: Up to Day 28

  2. Time to Cmax (Tmax)

    Tmax will be assessed.

    Time frame: Up to Day 28

  3. Plasma Concentrations at Pre-dose or at the End of a Dosing Interval (Ctrough)

    Ctrough will be assessed.

    Time frame: Up to Day 28

  4. Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau)

    AUCtau will be assessed.

    Time frame: Up to Day 28

  5. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Baseline to Day 129

07

Study locations

3 sites
  • Collaborative Neuroscience Research CNS /ID# 260270
    Los Alamitos, California 90720, United States
  • Acpru /Id# 255945
    Grayslake, Illinois 60030, United States
  • Hassman Research Institute Marlton Site /ID# 260271
    Marlton, New Jersey 08053, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Mar 2025, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2023
First posted
Sep 6, 2023
StartActual
Aug 31, 2023
Primary completionActual
Mar 4, 2025
CompletionActual
Mar 4, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06024239
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Aug 31, 2023
Primary completion
Mar 4, 2025
Completion
Mar 4, 2025
Last update
Mar 17, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-932

Start the discussion